Skip to main content

Table 1 Baseline characteristics of the study subjects

From: Creatinine- and cystatin C-based estimated glomerular filtration rate slopes for the prediction of kidney outcome: a comparative retrospective study

Variable

n = 1323

Age, median (IQR), years

56 (45–68)

Female, n (%)

473 (36)

Body mass index, median (IQR), kg/m2

23.9 (21.7–26.3)

Diabetes, n (%)

449 (34)

Hypertension, n (%)

1165 (88)

Malignancy, n (%)

202 (15)

Kidney transplantation, n (%)

238 (18)

ACE-I or ARB treatment, n (%)

675 (51)

Spironolactone treatment, n (%)

41 (3)

CKD stagea, n (%) 3a/3b/4/5

450 (34)/471 (36)/337 (25)/65 (5)

Creatinine, median (IQR), mg/dL

eGFRcr, median (IQR), mL/min/1.73 m2

1.8 (1.5–2.3)

39 (27–48)

Cystatin C, median (IQR), mg/L

eGFRcys, median (IQR), mL/min/1.73 m2

1.7 (1.4–2.2)

38 (27–50)

eGFRcr-cys, median (IQR), mL/min/1.73 m2

38 (27–49)

Serum albumin, median (IQR), g/dL

4.3 (4.0–4.5)

PCR, median (IQR), μg/mg Cr

0.50 (0.16–1.33)

  1. Values are expressed as median (interquartile range) or percentage, as appropriate
  2. ACE-I Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, CKD Chronic kidney disease, KT Kidney transplantation, GN Glomerulonephritis, DM Diabetes mellitus, PCKD Polycystic kidney disease, eGFR Estimated glomerular filtration rate, eGFRcr Creatinine-based eGFR, eGFRcys Cystatin C-based eGFR
  3. aCKD stages were categorized according to baseline eGFRcr-cys values